Combinations of the Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor Gs-1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Previously Treated, Indolent Non-Hodgkin Lymphoma: Results From a Phase I Study
Year: 2012
Type: article
Study design: Clinical Trial
Source: Blood
Authors: Nathan H Fowler, Sven de Vos, Marshall T. Schreeder, John P. Leonard, Ian W. Flinn, Steve Coutre, Nina D. Wagner-Johnston, Jeff Sharman, Ralph V. Boccia, Jacqueline C. Barrientos, Thomas E. Boyd, Leanne M. Holes, Brian J. Lannutti, David Johnson, Thomas M. Jahn, Langdon L Miller, Wayne R Godfrey
Institutions: The University of Texas MD Anderson Cancer Center, University of California, Los Angeles, Clearview Cancer Institute, Weill Cornell Medicine, Sarah Cannon, Stanford Medicine, Stanford University, Washington University in St. Louis, The US Oncology Network, Center for Cancers and Blood Disorders, Hofstra University, Virginia Mason Memorial
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2560550453